The ATMP and CDMO deal maker

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with David Anderson, General Partner at Ampersand Capital Partners. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering: What a world-class healthcare PE company looks for, and is repelled by, in a pharma services acquisition target Behind the scenes of some of the biggest M&A deals in the outsourcing space in recent years - including Brammer Bio’s sale to Thermo Beyond the dollars of a deal - the importance of relationships, trust and straight talk What life is like on the board of several fast-growing advanced therapy companies Insights on key market tailwinds and where Ampersand plans to invest its $1.2bn fund David joined Ampersand in 2010. Previously, David spent six years with Covington Associates, a specialty investment bank focused on middle-market M&A in the healthcare sector. Prior to Covington, he spent five years as a consultant for Boston Healthcare Associates. David’s board seats include Genezen, Arranta Bio, StageBio, Protogene, BioClinica, Brammer Bio, Cellero, and Vibalogics. David holds a B.Sc. from the University of Aberdeen, a Ph.D. in Immunology from the University of Sheffield, and an M.B.A. from Babson College. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.